Jenny Viklund

Biopharmaceuticals R&D, AstraZeneca
Moelndal, O 43183, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors.

Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors.

Journal: ACS medicinal chemistry letters

Published: January 20, 2026

Discovery of AZD4144, a Selective and Potent NLRP3 Inhibitor for the Treatment of Inflammatory Diseases.

Discovery of AZD4144, a Selective and Potent NLRP3 Inhibitor for the Treatment of Inflammatory Diseases.

Journal: Journal of medicinal chemistry

Published: July 09, 2025

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.

Journal: Molecular oncology

Published: August 23, 2023

Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies.

Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies.

Journal: Nature communications

Published: July 18, 2023

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.

Journal: Science advances

Published: April 23, 2019

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

Journal: Cancer letters

Published: May 04, 2018

Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.

Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.

Journal: Journal of medicinal chemistry

Published: February 28, 2018

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Journal: ACS chemical biology

Published: July 06, 2017

Therapeutic implications of tumor interstitial acidification.

Therapeutic implications of tumor interstitial acidification.

Journal: Seminars in cancer biology

Published: December 29, 2016

Pathobiology and Therapeutic Implications of Tumor Acidosis.

Pathobiology and Therapeutic Implications of Tumor Acidosis.

Journal: Current medicinal chemistry

Published: November 07, 2016

Creation of Novel Cores for β-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy.

Creation of Novel Cores for β-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy.

Journal: ACS medicinal chemistry letters

Published: January 29, 2014

Potency prediction of β-secretase (BACE-1) inhibitors using density functional methods.

Potency prediction of β-secretase (BACE-1) inhibitors using density functional methods.

Journal: Journal of chemical information and modeling

Published: January 25, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026